New Hope for Patients with Brain Disorders

Introducing a breakthrough, validated approach to developing first-in-class and best-in-class drugs to treat mental illness.


Drug Discovery for Brain Disorders Has Stagnated

It’s been 40 years since a truly novel drug has been approved for brain disorders – largely because the standard, target-based approach adopted by biopharma has proven ineffective against CNS dysfunction.

It’s Time for a New, Unbiased Approach

We recognized this industry-wide problem, and did something about it. We embarked on a radically different, unbiased approach – validated and funded by the NIMH – to build a robust pipeline of clinical programs to treat brain disorders, giving hope to millions of patients and their families who suffer every day.

We’re Transforming the CNS Drug Discovery Paradigm

The prevailing approach used by pharma to identify CNS targets is flawed and highly ineffective. Instead of merely tweaking current strategies, we’re coming at it from an entirely new angle for greater efficiency and efficacy.


By using an unbiased approach to systems neuroscience, we examine the entire brain circuitry rather than simply a single drug target, allowing the system to reveal what’s useful.


Our flexible, privileged chemistry platform can be applied to multiple CNS indications and is highly effective at identifying drug-like compounds, leading to efficient design.


Together with our AI partners, Exscientia and PsychoGenics, we optimize desirable small molecules for normalizing the behavioral symptoms of brain disorders.

First-in-Class & Best-in-Class Drugs Discovered by Blue Oak

Our approach has received clinical validation through R&D we've pioneered over the past 15 years. Our first pre-clinical candidate is for bipolar depression, with additional programs for treatment-resistant depression, schizophrenia, and geriatric psychosis.

Thomas H. Large, Ph.D. President and CEO
Kerry L. Spear, Ph.D. Chief Science Officer

Leading Experts in CNS Drug R&D

15+ Year Partnership with 15+ IND/CTAS

Our founders, Thomas Large and Kerry Spear, are internationally-recognized experts in translational medicine, neuropharmacology and medicinal chemistry. Both have held leadership roles at leading pharmaceutical companies like Eli Lilly and Sunovion.


News from Blue Oak

Nimh Award

Blue Oak awarded a $2.9M Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health (NIMH) to develop next generation drugs for bipolar disorder.


Press Release

US startup Blue Oak Pharma has joined a lengthening list of companies turning to Exscientia of the UK for its expertise in applying artificial intelligence to drug discovery.

October 14, 2020 US startup Blue Oak Pharma has joined

Fund Raising

Viva Biotech Holdings leads Series A funding round, alongside ShangPharma Innovation and JMCR Family Partners, to advance the Blue Oak R&D pipeline in psychiatric drugs.


SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Actions


Blue Oak delivers a podium presentation at the Keystone Meeting on Phenotypic Drug Discovery describing a systems neurobiology approach to discovering the next generation of drugs for bipolar depression.

Nimh Award

Blue Oak awarded a $900,000 Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health (NIMH) to develop next generation drugs for bipolar disorder.

NIMH Funding

Blue Oak has received sustained funding from the National Institute of Mental Health (NIMH) to support drug discovery and clinical development.

Key Partnerships

Shang Pharma innovation
Sprout BioVentures
IVA Biotech
JMCR Family Office
SB Drug Discovery

Join Our Fight Against Brain Disorders

For investment or partnership opportunities or to learn more about our clinical programs, contact our team today.

Contact us